XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
XTL Biopharmaceuticals Ltd. has entered into a settlement agreement involving an adjustment of American Depositary Shares and warrants with its subsidiary, The Social Proxy Ltd. The resolution saw the return of over 372 million ordinary shares to XTL’s treasury. XTL continues to explore strategic collaborations in the Lupus treatment space while expanding its portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.